Compound class:
Peptide or derivative
Comment: SNG001 is a recombinant form of human interferon β, interferon beta-1a, in a formulation that can be administered via a neubliser, directly to the lungs. Synairgen originally developed SNG001 as a therapy for virally-induced exacerbations of COPD, but have rapidly re-deployed it for SARS-CoV-2 infection. The EU Clinical Trials Register entry for Synairgen's study of SNG001 in COVID-19 patients (EudraCT Number: 2020-001023-14) contains the detail that SNG001 is "Interferon beta-1a".
|
| Immunopharmacology Comments |
| Interferon-β1 is a type I interferon, that is a modulator of the innate immune response against viruses. Recombinant versions of IFN-β1 are already in clinical use to reduce relapses in patients with multiple sclerosis. |
